Tim Anderson
Stock Analyst at B of A Securities
(4.71)
# 166
Out of 5,030 analysts
46
Total ratings
80%
Success rate
20%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $198 → $204 | $193.22 | +5.58% | 8 | Oct 15, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $24.51 | +22.40% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $298.81 | -8.97% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $55.15 | +57.75% | 1 | Aug 28, 2025 | |
| MTSR Metsera | Maintains: Buy | $45 → $50 | $52.99 | -5.64% | 2 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $12.79 | +95.47% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $229.57 | -11.14% | 7 | Apr 28, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $578.05 | -5.37% | 2 | Apr 17, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $122.81 | +2.60% | 3 | Mar 5, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $26.01 | +30.72% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $112 | $84.79 | +32.09% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $43.63 | +44.40% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $143.00 | +24.48% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $802.83 | +24.19% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $131.43 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $84.69 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Oct 15, 2025
Maintains: Neutral
Price Target: $198 → $204
Current: $193.22
Upside: +5.58%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $24.51
Upside: +22.40%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $298.81
Upside: -8.97%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $55.15
Upside: +57.75%
Metsera
Aug 28, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $52.99
Upside: -5.64%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $12.79
Upside: +95.47%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $229.57
Upside: -11.14%
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $578.05
Upside: -5.37%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $122.81
Upside: +2.60%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $26.01
Upside: +30.72%
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $84.79
Upside: +32.09%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $43.63
Upside: +44.40%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $143.00
Upside: +24.48%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $802.83
Upside: +24.19%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $131.43
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $84.69
Upside: -